Request Demo
Monte Rosa Therapeutics to Join Upcoming Investor Conferences
30 August 2024
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company, focuses on developing innovative molecular glue degrader (MGD)-based medications. The company recently announced participation in multiple upcoming investor conferences.
The management team of Monte Rosa will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 4, 2024. Additionally, Markus Warmuth, M.D., the Chief Executive Officer, will engage in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston, MA. This chat is scheduled for September 5, 2024, at 2:15 p.m. ET. For those interested, a webcast of the fireside chat will be available through the “Events & Presentations” section on Monte Rosa’s website, and it will be archived for 30 days following the presentation.
Monte Rosa Therapeutics specializes in developing highly selective MGD medicines aimed at treating serious conditions in oncology, autoimmune, and inflammatory diseases. MGDs are unique small molecule protein degraders with the potential to address diseases that other treatment modalities cannot effectively target.
The company’s proprietary QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines advanced AI-guided chemistry, comprehensive chemical libraries, structural biology, and proteomics. This innovative platform enables the identification of degradable protein targets and the rational design of MGDs with remarkable selectivity. The QuEEN engine opens up a broad and diverse target space, encompassing well-validated biological pathways across various therapeutic domains.
Monte Rosa’s industry-leading pipeline of MGDs includes developments in oncology, autoimmune and inflammatory conditions, among others. The company has also formed a strategic partnership with Roche, aiming to discover and develop MGDs for targets in cancer and neurological diseases that were previously considered undruggable.
Monte Rosa remains committed to pioneering the development of MGD-based therapies to provide new treatment options for patients with serious diseases.
The management team of Monte Rosa will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 4, 2024. Additionally, Markus Warmuth, M.D., the Chief Executive Officer, will engage in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston, MA. This chat is scheduled for September 5, 2024, at 2:15 p.m. ET. For those interested, a webcast of the fireside chat will be available through the “Events & Presentations” section on Monte Rosa’s website, and it will be archived for 30 days following the presentation.
Monte Rosa Therapeutics specializes in developing highly selective MGD medicines aimed at treating serious conditions in oncology, autoimmune, and inflammatory diseases. MGDs are unique small molecule protein degraders with the potential to address diseases that other treatment modalities cannot effectively target.
The company’s proprietary QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines advanced AI-guided chemistry, comprehensive chemical libraries, structural biology, and proteomics. This innovative platform enables the identification of degradable protein targets and the rational design of MGDs with remarkable selectivity. The QuEEN engine opens up a broad and diverse target space, encompassing well-validated biological pathways across various therapeutic domains.
Monte Rosa’s industry-leading pipeline of MGDs includes developments in oncology, autoimmune and inflammatory conditions, among others. The company has also formed a strategic partnership with Roche, aiming to discover and develop MGDs for targets in cancer and neurological diseases that were previously considered undruggable.
Monte Rosa remains committed to pioneering the development of MGD-based therapies to provide new treatment options for patients with serious diseases.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.